Results 71 to 80 of about 798 (134)

Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. [PDF]

Cancer Med
Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T, Yoneyama F, Hamaya T, Togashi K, Fujita N, Okamoto T, Ohyama C, Hatakeyama S.   +12 more
europepmc   +1 more source

Synthetic estrogen and progestin effects on the myogenic program following damage in C2C12 murine myoblasts. [PDF]

Physiol Rep
Wageh M, Kamal M, Parise G.
europepmc   +1 more source

Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC. [PDF]

Future Oncol
Veccia A, Basso U, Cattrini C, Ermacora P, Maruzzo M, Alberti M, Anesi C, Bimbatti D, Cani M, Crespi V, Farinea G, Kadrija D, Kinspergher S, Lai E, Lay L, Maines F, Mennitto A, Pierantoni F, Samuelly A, Urban S, Caffo O, Buttigliero C.   +21 more
europepmc   +1 more source

Establishing a Quantitative Framework for Combined Oral Contraceptives: Evaluating the Impact of Drug-Drug Interactions on Exposure and Clinical (Surrogate) Efficacy Endpoints. [PDF]

J Clin Pharmacol
Chun D, Chen H, Cicali B, Guzy S, Hoechel J, Jiao T, Vozmediano V, Schmidt S.   +7 more
europepmc   +1 more source

Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. [PDF]

Int J Clin Pharm
Pons-Fuster E, Gonzalez-Ponce CM, Ros-Martinez S, Fernández-Ávila JJ, Díaz-Carrasco MS, Espuny-Miró A.   +5 more
europepmc   +1 more source

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer. [PDF]

Clin Transl Sci
Norton N, Larson NB, Jenkins GD, Beumer JH, Langevin B, Gobbaru J, Morris MJ, Nakamura Y, Kroetz DL, Zhu HJ, O'Donnell PH, Lewis LD, Hertz DL.   +12 more
europepmc   +1 more source

Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan. [PDF]

J Cancer Res Clin Oncol
Huang WK, Su PJ, Chen CC, Chang CF, Yu SM, Hsieh MJ, Tsai ML, Chen TH, Chu PH, Hsieh IC, Pang ST, Chen DY.   +11 more
europepmc   +1 more source

Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel. [PDF]

Medicina (Kaunas)
Taban H, Erman M, Guven DC, Aktas BY, Yilmaz F, Yaşar S, Yildirim HC, Aslan F, Aksoy S.   +8 more
europepmc   +1 more source

Efficacy of a four-drug combined regimen compared to uterine curettage in the treatment of incomplete medical abortion: a prospective observational study. [PDF]

J Health Popul Nutr
Feng Y, Zhang L.
europepmc   +1 more source

Metabolism of delta 4-androstene-3beta, 17beta-diol and delta 4-androstene-3alpha, 17beta-diol in vitro.

The Journal of biological chemistry, 2002
R I, DORFMAN, M, GUT, F, UNGAR
openaire   +1 more source